SI1427720T1 - 3-substituirani-4-pirimidonski derivati - Google Patents
3-substituirani-4-pirimidonski derivatiInfo
- Publication number
- SI1427720T1 SI1427720T1 SI200230816T SI200230816T SI1427720T1 SI 1427720 T1 SI1427720 T1 SI 1427720T1 SI 200230816 T SI200230816 T SI 200230816T SI 200230816 T SI200230816 T SI 200230816T SI 1427720 T1 SI1427720 T1 SI 1427720T1
- Authority
- SI
- Slovenia
- Prior art keywords
- sup
- sub
- substituted
- ring
- group
- Prior art date
Links
- -1 3-substituted-4-pyrimidone Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000008318 pyrimidones Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 108010061506 tau-protein kinase Proteins 0.000 abstract 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001331677 | 2001-09-21 | ||
| JP2001331678 | 2001-09-21 | ||
| JP2001331675 | 2001-09-21 | ||
| JP2001331674 | 2001-09-21 | ||
| PCT/JP2002/009685 WO2003037888A1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
| EP02772871A EP1427720B1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1427720T1 true SI1427720T1 (sl) | 2009-08-31 |
Family
ID=27482651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200230816T SI1427720T1 (sl) | 2001-09-21 | 2002-09-20 | 3-substituirani-4-pirimidonski derivati |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7427615B2 (sl) |
| EP (1) | EP1427720B1 (sl) |
| JP (1) | JP4347050B2 (sl) |
| KR (1) | KR100881821B1 (sl) |
| CN (1) | CN100488958C (sl) |
| AT (1) | ATE424393T1 (sl) |
| AU (1) | AU2002337499B2 (sl) |
| BR (1) | BR0212892A (sl) |
| CA (1) | CA2460121C (sl) |
| CY (1) | CY1110317T1 (sl) |
| DE (1) | DE60231414D1 (sl) |
| DK (1) | DK1427720T3 (sl) |
| EA (1) | EA007576B1 (sl) |
| ES (1) | ES2323576T3 (sl) |
| HU (1) | HUP0401900A3 (sl) |
| IL (2) | IL160700A0 (sl) |
| MX (1) | MXPA04002662A (sl) |
| NO (1) | NO325781B1 (sl) |
| NZ (1) | NZ531636A (sl) |
| PL (1) | PL368671A1 (sl) |
| PT (1) | PT1427720E (sl) |
| SI (1) | SI1427720T1 (sl) |
| TW (1) | TWI265164B (sl) |
| WO (1) | WO2003037888A1 (sl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| AR043700A1 (es) | 2001-09-21 | 2005-08-10 | Mitsubishi Pharma Corp | Derivados de 3-substituida-4-pirimidona |
| MXPA05006394A (es) * | 2002-12-16 | 2007-04-16 | Mitsubishi Pharma Corp | Derivados de 4-pirimidona 3-sustituida. |
| CN1894234A (zh) | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| RU2006107553A (ru) | 2003-08-13 | 2007-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз |
| US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| CN102140090A (zh) | 2004-03-15 | 2011-08-03 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| TW200621760A (en) * | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
| ZA200703383B (en) * | 2004-09-29 | 2009-05-27 | Mitsubishi Pharma Corp | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
| WO2006041404A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-compounds and uses thereof |
| EP1802588A4 (en) * | 2004-10-15 | 2010-02-17 | Astrazeneca Ab | SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| DK1942898T4 (da) | 2005-09-14 | 2014-06-02 | Takeda Pharmaceutical | Dipeptidylpeptidase-inhibitorer til behandling af diabetes |
| CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
| TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
| KR20090052884A (ko) * | 2006-08-23 | 2009-05-26 | 화이자 프로덕츠 인크. | Ｇｓｋ-3 억제제로서의 피리미돈 화합물 |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| AR064660A1 (es) * | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JP5449147B2 (ja) * | 2007-09-14 | 2014-03-19 | サノフイ | タウプロテインキナーゼ阻害剤としての、３−メチル−２−（（２ｓ）−２−（４−（３−メチル−１，２，４−オキサジアゾール−５−イル）フェニル）モルホリノ）−６−（ピリミジン−４−イル）ピリミジン−４（３ｈ）−オン |
| TW200927134A (en) * | 2007-09-14 | 2009-07-01 | Mitsubishi Tanabe Pharma Corp | 6-pyrimidinyl-pyrimid-2-one derivative |
| AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
| WO2011019090A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
| WO2011019089A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
| WO2013071232A1 (en) * | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules |
| SG11201702185UA (en) | 2014-09-29 | 2017-04-27 | Chemocentryx Inc | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
| JP7339733B2 (ja) | 2016-01-14 | 2023-09-06 | ケモセントリックス，インコーポレイティド | Ｃ３腎症を処置する方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4935631B1 (sl) | 1970-12-28 | 1974-09-25 | ||
| JPS559099B2 (sl) | 1972-08-07 | 1980-03-07 | ||
| JPS4935633A (sl) | 1972-08-09 | 1974-04-02 | ||
| JPS5124008B2 (sl) | 1972-08-10 | 1976-07-21 | ||
| JPS4935632A (sl) | 1972-08-10 | 1974-04-02 | ||
| JPS5271481A (en) | 1975-12-10 | 1977-06-14 | Yoshitomi Pharmaceut Ind Ltd | Synthesis of pyridylpyrimidines |
| JPS52139085A (en) | 1976-05-13 | 1977-11-19 | Hokuriku Pharmaceutical | 22allylpiperazine derivative and method for its preparation |
| US4507302A (en) | 1979-03-19 | 1985-03-26 | The Upjohn Company | Method for treating arthritis with 6-aryl pyrimidine compounds |
| US4619933A (en) | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
| US4725600A (en) | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
| DE58908208D1 (de) | 1988-07-29 | 1994-09-22 | Ciba Geigy Ag | Thiouracile als Stabilisatoren für chlorhaltige Polymerisate. |
| DE69233723T2 (de) | 1991-12-06 | 2009-02-05 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit |
| DE4206145A1 (de) | 1992-02-28 | 1993-09-02 | Basf Ag | Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide |
| JP3324611B2 (ja) | 1992-07-03 | 2002-09-17 | 三菱化学株式会社 | タウ蛋白質のリン酸化方法 |
| US5300477A (en) * | 1992-07-17 | 1994-04-05 | Rohm And Haas Company | 2-arylpyrimidines and herbicidal use thereof |
| JPH06329551A (ja) | 1993-03-22 | 1994-11-29 | Mitsubishi Kasei Corp | アルツハイマー病の予防または治療薬およびそのスクリーニング方法 |
| JPH07179442A (ja) * | 1993-10-08 | 1995-07-18 | Sagami Chem Res Center | ４−イミノオキサゾリジン−２−オン誘導体、それらの製造方法、及びそれらを有効成分とする除草剤 |
| BR9407799A (pt) | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
| JP2002514195A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
| BR9713850A (pt) | 1996-12-05 | 2000-02-29 | Amgen Inc | Composto, composição farmacêutica, processos para profilaxia ou tratamento de infecção e de doenças, para diminuir concentrações no plasma de qualquer um ou de ambos tnf-. e o;-1 de qualquer um ou de ambos il-6 e il-8, para profilaxia ou tratamento da doença diabetes e de um distúrbio da dor em um mamìfero, para dimunuir a produção de prostaglandinas em um mamìfero, e, para dimuir a atividade da enzima ciclooxigenase em um mamìfero. |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| EP1261327B1 (en) | 2000-02-25 | 2005-04-27 | F.Hoffmann-La Roche Ag | Adenosine receptor modulators |
| WO2001070728A1 (en) | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-[nitrogen-heterocyclic]pyrimidone derivatives |
| EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| AR043700A1 (es) | 2001-09-21 | 2005-08-10 | Mitsubishi Pharma Corp | Derivados de 3-substituida-4-pirimidona |
| MXPA05006394A (es) | 2002-12-16 | 2007-04-16 | Mitsubishi Pharma Corp | Derivados de 4-pirimidona 3-sustituida. |
| TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
-
2002
- 2002-09-20 NZ NZ531636A patent/NZ531636A/en not_active IP Right Cessation
- 2002-09-20 AT AT02772871T patent/ATE424393T1/de active
- 2002-09-20 JP JP2003540169A patent/JP4347050B2/ja not_active Expired - Fee Related
- 2002-09-20 CA CA2460121A patent/CA2460121C/en not_active Expired - Fee Related
- 2002-09-20 TW TW091121655A patent/TWI265164B/zh not_active IP Right Cessation
- 2002-09-20 DE DE60231414T patent/DE60231414D1/de not_active Expired - Lifetime
- 2002-09-20 PL PL02368671A patent/PL368671A1/xx unknown
- 2002-09-20 EP EP02772871A patent/EP1427720B1/en not_active Expired - Lifetime
- 2002-09-20 PT PT02772871T patent/PT1427720E/pt unknown
- 2002-09-20 CN CNB028184696A patent/CN100488958C/zh not_active Expired - Fee Related
- 2002-09-20 SI SI200230816T patent/SI1427720T1/sl unknown
- 2002-09-20 WO PCT/JP2002/009685 patent/WO2003037888A1/en not_active Ceased
- 2002-09-20 KR KR1020047004112A patent/KR100881821B1/ko not_active Expired - Fee Related
- 2002-09-20 IL IL16070002A patent/IL160700A0/xx unknown
- 2002-09-20 AU AU2002337499A patent/AU2002337499B2/en not_active Ceased
- 2002-09-20 EA EA200400453A patent/EA007576B1/ru not_active IP Right Cessation
- 2002-09-20 ES ES02772871T patent/ES2323576T3/es not_active Expired - Lifetime
- 2002-09-20 HU HU0401900A patent/HUP0401900A3/hu unknown
- 2002-09-20 DK DK02772871T patent/DK1427720T3/da active
- 2002-09-20 US US10/489,606 patent/US7427615B2/en not_active Expired - Fee Related
- 2002-09-20 MX MXPA04002662A patent/MXPA04002662A/es active IP Right Grant
- 2002-09-20 BR BR0212892-6A patent/BR0212892A/pt not_active Application Discontinuation
-
2004
- 2004-03-03 IL IL160700A patent/IL160700A/en not_active IP Right Cessation
- 2004-04-20 NO NO20041600A patent/NO325781B1/no not_active IP Right Cessation
-
2009
- 2009-05-28 CY CY20091100562T patent/CY1110317T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL368671A1 (en) | 2005-04-04 |
| MXPA04002662A (es) | 2004-11-22 |
| KR100881821B1 (ko) | 2009-02-03 |
| CY1110317T1 (el) | 2015-01-14 |
| US20050090490A1 (en) | 2005-04-28 |
| HUP0401900A2 (hu) | 2004-12-28 |
| DE60231414D1 (de) | 2009-04-16 |
| NZ531636A (en) | 2005-11-25 |
| EA200400453A1 (ru) | 2004-08-26 |
| EA007576B1 (ru) | 2006-12-29 |
| BR0212892A (pt) | 2004-08-03 |
| CN1556804A (zh) | 2004-12-22 |
| HUP0401900A3 (en) | 2005-08-29 |
| JP4347050B2 (ja) | 2009-10-21 |
| WO2003037888A1 (en) | 2003-05-08 |
| ATE424393T1 (de) | 2009-03-15 |
| NO325781B1 (no) | 2008-07-14 |
| KR20040054689A (ko) | 2004-06-25 |
| EP1427720B1 (en) | 2009-03-04 |
| NO20041600L (no) | 2004-06-16 |
| ES2323576T3 (es) | 2009-07-21 |
| EP1427720A1 (en) | 2004-06-16 |
| AU2002337499B2 (en) | 2007-08-23 |
| PT1427720E (pt) | 2009-04-27 |
| US7427615B2 (en) | 2008-09-23 |
| CN100488958C (zh) | 2009-05-20 |
| CA2460121C (en) | 2010-11-02 |
| TWI265164B (en) | 2006-11-01 |
| DK1427720T3 (da) | 2009-05-04 |
| JP2005510506A (ja) | 2005-04-21 |
| CA2460121A1 (en) | 2003-05-08 |
| IL160700A0 (en) | 2004-08-31 |
| IL160700A (en) | 2009-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL160700A0 (en) | 3-substituted-4-pyrimidone derivatives | |
| EA200400452A1 (ru) | Производные 3-замещенных 4-пиримидонов | |
| UA83243C2 (ru) | Соединения, которые ингибируют натриезависимый переносчик глюкозы | |
| GB2393653A (en) | DNA-PK inhibitors | |
| DE60236851D1 (en) | Pyrimidinmatrixmetalloproteinaseinhibitoren | |
| NO20060219L (no) | Forbindelser | |
| MY146532A (en) | Thiazole derivative | |
| JO2668B1 (en) | Isoczazolins for controlling invertebrate insects | |
| NO20004485L (no) | Sykloalkenderivater, deres fremstilling og anvendelse | |
| EP1008592A3 (en) | Cyclic amide derivatives which inhibit cathepsin K | |
| EP1184373A4 (en) | TRICYCLIC CONNECTIONS | |
| TW200612920A (en) | Novel imidazolidine derivatives | |
| NO20053449L (no) | 3-substituerte 4-pyrimidonderivater | |
| TW200613297A (en) | Pyrazole derivatives | |
| TW200609218A (en) | Bicyclic compounds | |
| EP1674454A4 (en) | SUBSTITUTED 2-AMINO-1,2,4-TRIAZOLO 1,5-A-PYRIMIDINE DERIVATIVE AND THE USE THEREOF | |
| TW200740757A (en) | Carboxamide compound and use of the same | |
| KR970021067A (ko) | 1-아지닐-테트라졸리논 | |
| TW200738679A (en) | Carboxamide compound and use of the same | |
| EP1104756A4 (en) | Brassionosteroid biosynthesis inhibitors | |
| NO983656L (no) | Heterocyklyl-ergolinderivater som 5-HT1A reseptorligander | |
| IL157453A0 (en) | Hiv inhibiting n-aminoimidazole derivatives | |
| TH102358A (th) | อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3 | |
| TH65446A (th) | อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3 | |
| TW200504088A (en) | Avermectin B1 monosaccharide derivatives |